دورية أكاديمية

When Waldenström macroglobulinemia hits the kidney: Description of a case series and management of a 'rare in rare' scenario

التفاصيل البيبلوغرافية
العنوان: When Waldenström macroglobulinemia hits the kidney: Description of a case series and management of a 'rare in rare' scenario
المؤلفون: Nicolò Danesin, Greta Scapinello, Dorella Del Prete, Elena Naso, Tamara Berno, Andrea Visentin, Laura Bonaldi, Annalisa Martines, Roberta Bertorelle, Fabrizio Vianello, Carmela Gurrieri, Renato Zambello, Chiara Castellani, Marny Fedrigo, Stefania Rizzo, Annalisa Angelini, Livio Trentin, Francesco Piazza
المصدر: Cancer Reports, Vol 7, Iss 4, Pp n/a-n/a (2024)
بيانات النشر: Wiley, 2024.
سنة النشر: 2024
المجموعة: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية: amyloidosis, kidney disease, lymphoma, lymphoproliferative disorders, Waldenström macroglobulinemia, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
الوصف: Abstract Background Renal injury related to Waldenström macroglobulinemia (WM) occurs in approximately 3% of patients. Kidney biopsy is crucial to discriminate between distinct histopathological entities such as glomerular (amyloidotic and non‐amyloidotic), tubulo‐interstitial and non‐paraprotein mediated renal damage. In this context, disease characterization, management, relationship between renal, and hematological response have been poorly explored. We collected clinical, genetic and laboratory data of seven cases of biopsy‐proven renal involvement by WM managed at our academic center and focused on three cases we judged paradigmatic discussing their histopathological patterns, clinical features, and therapeutic options. Case In this illustrative case series, we confirm that serum creatinine levels and 24 h proteinuria are parameters that when altered should prompt the clinical suspicion of WM‐related renal involvement, even if at present there are not precise cut‐off levels recommending the execution of a renal biopsy. In our series AL Amyloidosis (n = 3/7) and tubulo‐interstitial infiltration by lymphoma cells (n = 3/7) were the two more represented entities. BTKi did not seem to improve renal function (Case 1), while bortezomib‐based regimens demonstrated a beneficial activity on the hematological and organ response, even when used as second‐line therapy after chemoimmunotherapy (Case 3) and also with coexistence of anti‐MAG neuropathy (Case 2). In case of poor response to bortezomib, standard chemoimmunotherapy (CIT), such as rituximab‐bendamustine, represents an effective option (Case 1, 6, and 7). In our series, CIT generates durable responses more frequently in cases with amyloidogenic renal damage (Case 1, 5, and 7). Conclusion In this illustrative case series, we confirm that serum creatinine levels and 24 h proteinuria are parameters that when altered should prompt the clinical suspicion of WM‐related renal involvement, even if at present there are not precise cut‐off levels recommending the execution of a renal biopsy. Studies with higher numerosity are needed to better clarify the pathological and clinical features of renal involvement during WM and to determine the potential benefit of different therapeutic regimens according to the histopathological subtypes.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2573-8348
Relation: https://doaj.org/toc/2573-8348
DOI: 10.1002/cnr2.2062
URL الوصول: https://doaj.org/article/9af98db38b974f8aaa015cea7c106637
رقم الأكسشن: edsdoj.9af98db38b974f8aaa015cea7c106637
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:25738348
DOI:10.1002/cnr2.2062